Clinical trials: Extensive Stage Small Cell Lung Cancer (ES-SCLC)
- Condition Extensive Stage Small Cell Lung Cancer (ES-SCLC)
- Funder type Industry (pharma, biotech, devices)
Small Cell Lung Cancer (SCLC)
A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604)
The purpose of this study is to assess the safety and efficacy of pembrolizumab plus standard of care (SOC) chemotherapy (etoposide/platinum [EP]) in participants with newly diagnosed extensive stage small cell lung cancer…
- Trial name
- NCT03066778
- Testing
- Pembrolizumab, Normal saline solution, Carboplatin
- Where
- 148 sites in United States, Australia and 17 more
- Volunteers
- 453 people
- Sponsor
- Merck Sharp & Dohme LLC
Extensive Stage-Small Cell Lung Cancer (ES-SCLC)
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) ABBV-706 in Combination With Alveltamig and Atezolizumab for Adults Participants With Extensive Stage-Small Cell Lung Cancer
Small cell lung cancer (SCLC) is a type of lung cancer that accounts for approximately 15-17% of all lung cancers. It is characterized by aggressive and rapid growth and early spread to distant sites.
- Trial name
- NCT07895043
- Testing
- Alveltamig, Atezolizumab, ABBV-706
- Volunteers
- 80 people
- Sponsor
- AbbVie
Extensive Stage Small Cell Lung Cancer
To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC
This is a randomized, open-label study of Serplulimab plus chemotherapy (Carboplatin-Etoposide) in comparison with Atezolizumab plus chemotherapy in previously untreated US patients with ES-SCLC.
- Trial name
- NCT05468489
- Testing
- Serplulimab + chemotherapy (carboplatin-etoposide), Atezolizumab + chemotherapy (carboplatin-etoposide)
- Where
- 67 sites in United States
- Volunteers
- 200 people
- Sponsor
- Shanghai Henlius Biotech
SCLC
A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC
PM8002 is a bispecific antibody targeting PD-L1 and VEGF. This study to evaluate the efficacy and safety of PM8002 in combination with etoposide and platinum in first-line treatment of extensive-stage small cell lung cancer
- Trial name
- NCT05844150
- Testing
- PM8002, Platinum, Etoposide
- Where
- 17 sites in China
- Volunteers
- 50 people
- Sponsor
- Biotheus Inc.
SCLC, Extensive Stage
Anti-PD-1 and VEGF Bispecific Antibody AK112 in Combination With Chemotherapy in Patients With ES-SCLC
Phase Ib open label, multicenter study to evaluate the efficacy and safety of anti-PD-1 and VEGF bispecific antibody (AK112) combined with chemotherapy in patients with ES-SCLC.
- Trial name
- NCT05116007
- Testing
- AK112, Etoposide, Carboplatin
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Akeso
Small Cell Lung Cancer
Study of Amrubicin With or Without Cisplatin Versus Etoposide-cisplatin for Extensive Stage Small Cell Lung Cancer
The purpose of the study is to document the activity and safety of single agent amrubicin, amrubicin combined with cisplatin, and etoposide combined with cisplatin as first-line treatment in extensive disease small cell lung…
- Trial name
- NCT00388960
- Testing
- Amrubicin, Cisplatin, Etoposide
- Where
- 25 sites in Belgium, Italy and 3 more
- Volunteers
- 99 people
- Sponsor
- Celgene
SCLC, Extensive Stage
A Single-arm, Open-label, Phase II Study to Evaluate Efficacy, Safety and Pharmacokinetics of HLX10 + Chemotherapy in Patients With ES-SCLC
Evaluate Clinical Efficacy, Safety and Pharmacokinetics of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) in Combination with Chemotherapy (Carboplatin-Etoposide) in Previously Untreated Japanese Patients…
- Trial name
- NCT06812260
- Testing
- HLX10+chemo
- Where
- Japan
- Volunteers
- 26 people
- Sponsor
- Shanghai Henlius Biotech
Small Cell Lung Cancer
A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC).
A study consisting of a dose-escalation phase and a dose-expansion phase to evaluate the safety, tolerability, pharmacokinetics, and efficacy of venetoclax in combination with atezolizumab, carboplatin, and etoposide.
- Trial name
- NCT04422210
- Testing
- Venetoclax, Atezolizumab, Carboplatin
- Where
- 5 sites in United States, Denmark and 2 more
- Volunteers
- 2 people
- Sponsor
- Hoffmann-La Roche
Small Cell Lung Cancer
SC0245 and Irinotecan in Treating Patients With Relapsed Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
This study is a single arm, multi-center, open label phase Ib/II study of SC0245 and Irinotecan combination therapy in subjects with extensive-stage small cell lung cancer (ES-SCLC) as a second therapy.
- Trial name
- NCT05731518
- Testing
- SC0245, Irinotecan
- Where
- China
- Volunteers
- 67 people
- Sponsor
- Biocity Biopharmaceutics Co., Ltd.
Extensive-stage Small Cell Lung Cancer (ES-SCLC), The Pre-cachexia or Cachexia Patients Who Have Not Received Systemic Treatment and Are Not Eligible for Curative Therapy
Nano-crystalline Megestrol Acetate Combined With Standard Treatment Versus Standard Treatment for First-line Extensive-stage Small Cell Lung Cancer in the Cachexia Phase
This study is a prospective, randomized, parallel-controlled clinical trial, aiming to evaluate the efficacy and safety of nano-crystalline megestrol acetate combined with standard treatment compared to standard treatment alone…
- Trial name
- NCT06961201
- Testing
- Nano-crystalline Megestrol Acetate Oral Suspension, standard treatment
- Where
- China
- Volunteers
- 94 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Extensive-stage Small Cell Lung Cancer
Study of Carboplatin Plus Etoposide With or Without SHR-1316 in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)
This randomized, double-blinded, placebo-controlled phase III, multicenter study is designed to evaluate the safety and efficacy of SHR-1316 in combination with carboplatin plus (+) etoposide compared with treatment with placebo…
- Trial name
- NCT03711305
- Testing
- SHR-1316, Carboplatin, Etoposide
- Where
- 2 sites in China
- Volunteers
- 462 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
A Study of Ivonescimab in First-Line ES-SCLC
The goal of this clinical trial is to learn if different combinations of a drug called Ivonescimab, along with chemotherapy and other investigational drugs, are safe and effective for the initial treatment of adults with…
- Trial name
- NCT07245446
- Testing
- Ivonescimab, Cadonilimab, AK117
- Where
- 3 sites in China
- Volunteers
- 180 people
- Sponsor
- Akeso
Extensive Stage Small Cell Lung Cancer
First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)
This is a phase 1b study to assess the safety and tolerability of tarlatamab in combination with programmed death ligand (PD-L1) inhibition with and without chemotherapy.
- Trial name
- NCT05361395
- Testing
- Tarlatamab, Carboplatin, Etoposide
- Where
- 44 sites in United States, Australia and 13 more
- Volunteers
- 184 people
- Sponsor
- Amgen
Small-cell Lung Cancer, Extensive Stage Small-cell Lung Cancer
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
The main objective of the study is to compare the efficacy of tarlatamab in combination with durvalumab, carboplatin and etoposide to the combination of durvalumab, carboplatin and etoposide on prolonging overall survival (OS).
- Trial name
- DeLLphi-312 (NCT07005128)
- Testing
- Tarlatamab, Durvalumab, Carboplatin
- Where
- 164 sites in United States, Argentina and 24 more
- Volunteers
- 350 people
- Sponsor
- Amgen
SCLC,Extensive Stage
Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC
This study aims to determine the safety, preliminary antitumor activity, and pharmacokinetics (PK) of RYZ101 in combination with standard of care (SoC) therapy consisting of carboplatin + etoposide + atezolizumab in untreated…
- Trial name
- NCT05595460
- Testing
- RYZ101 Dose Level 1, RYZ101 Dose Level 2, RYZ101 Dose Level 3
- Where
- 13 sites in United States, Puerto Rico
- Volunteers
- 21 people
- Sponsor
- RayzeBio, Inc.
Small Cell Lung Carcinoma Extensive Disease
Durvalumab Plus Chemotherapy in ES-SCLC (Oriental)
This will be an open-label, single-arm, multicenter, Phase IIIb study to determine the safety of durvalumab + etoposide and cisplatin or carboplatin as first-line treatment in patients with extensive stage small-cell lung cancer.
- Trial name
- NCT04449861
- Testing
- Durvalumab plus chemotherapy
- Where
- 30 sites in China
- Volunteers
- 166 people
- Sponsor
- AstraZeneca
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy
This is a Phase I/II, open-label, non-randomized, multi-center study in patients with extensive-stage small cell lung cancer (ES-SCLC) to determine the recommended dose(s) (RD) and to evaluate the safety, tolerability and…
- Trial name
- NCT07564401
- Testing
- DJI136
- Where
- 7 sites in United States, Australia and 2 more
- Volunteers
- 80 people
- Sponsor
- Novartis Pharmaceuticals
Extensive-stage Small-cell Lung Cancer
Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan
This is a multicenter, randomized, double-blind, placebo-controlled study to assess whether trilaciclib administered prior to topotecan is non-inferior to placebo administered prior to topotecan with regard to overall survival.
- Trial name
- NCT05874401
- Testing
- Trilaciclib, Topotecan
- Where
- Spain
- Volunteers
- 302 people
- Sponsor
- Pharmacosmos A/S
Small Cell Lung Cancer
Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)
The primary objective of this study is to evaluate the safety and tolerability of tarlatamab in combination with YL201 with or without anti-PD-L1.
- Trial name
- (DeLLphi-310) (NCT06898957)
- Testing
- YL201, Tarlatamab, Durvalumab
- Where
- 36 sites in United States, Canada and 8 more
- Volunteers
- 29 people
- Sponsor
- Amgen
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Phase 1 Study of HS-20093 Combinations in Patients With Extensive Stage Small Cell Lung Cancer
This is a Phase I clinical study of HS-20093. The purpose of this study is to evaluate the safety, tolerability, PK and efficacy of HS-20093 in combination with Adebrelimab in patients with Extensive Stage Small Cell Lung Cancer…
- Trial name
- NCT07063407
- Testing
- HS-20093 in combination with Adebrelimab
- Volunteers
- 50 people
- Sponsor
- Shanghai Hansoh Biomedical Co., Ltd